ValuationLAB: Cassiopea Valuation Report "On spot for US launch"

Monday, June 22, 2020 @ 12:00 am

US approval of Winlevi in acne is a key catalyst which will be transformational for Cassiopea and marks the first new mode of action for acne in almost 40 years. Ideally, Cassiopea would like to acquire or merge with a US specialist derma company with a sales force to maximize the long-term value of Winlevi and its pipeline. The EUR 23.3 mn capital increase together with the Cosmo credit line provides sufficient cash beyond US approval of Winlevi, which should trigger a substantial revaluation.

Go to the Cassiopea Valuation Report

You may also be interested in

Life Science Cares launches in Switzerland

First international chapter of Life Science Cares established in Switzerland – bringing hearts and minds together by empowering the life sciences industry to support local communities.
April 19, 2024

ten23 health and Ypsomed collaborate on the commercialization of patch injector

ten23 health and Ypsomed today announced that they are entering into a strategic partnership to advance the commercialization of the YpsoDose wearable injector for subcutaneous self-injection of large-volume doses.
April 16, 2024

Orio Therapeutics raises CHF 500,000 for cardioprotective therapy development

Orio Therapeutics secures CHF 500,000 pre-seed funding to fuel the development of cardioprotective therapy for heart attack patients.
April 4, 2024

Newron valuation report "A pivotal year"

March 26, 2024

Stämm scales adherent cells by leveraging 3D printing and microfluidics

March 25, 2024

ten23 health: Partnership with SHL Medical

ten23 health, a leading Swiss Contract Development and Manufacturing Organization (CDMO) for sterile drugs, and SHL Medical, a world-leading provider of drug delivery devices, today announced their strategic partnership to provide a streamlined offering for pharmaceutical and biotech companies that require sterile drug/device combination products.
March 25, 2024